FIELD: medicine.
SUBSTANCE: the suggested transdermal therapeutic system (TTS) is indicated for percutaneous injection of tolterodin for several days. It is, also, described the method for its manufacturing. The suggested TTS is being a self-gluing lamellar matrix structure that contains methacrylate copolymer including ammonium groups, at least, one plastifier and up to 25 weight% tolterodin. TTS is of good tolerance by skin and is of good physical and chemical stability at prolonged storage and application, it, also, has got good adhesive properties and can provide the penetration of maximal quantity of active substance through skin.
EFFECT: higher efficiency of application.
8 cl, 2 dwg, 3 ex, 3 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| HIGHLY PURE 3,3-DIPHENYLPROPYLAMINO MONOESTERS | 2004 |
|
RU2394019C2 |
| TRANSDERMAL THERAPEUTIC SYSTEM FOR ADMINISTERING ACTIVE SUBSTANCE BUPRENORPHINE | 2007 |
|
RU2484822C2 |
| DEVICE FOR TRANSDERMAL INTRODUCTION OF ROTIGOTINE IN ORGANISM IN FORM OF BASE | 2003 |
|
RU2340339C2 |
| TRANSDERMAL THERAPEUTIC SYSTEM CONTAINING LAVAND OIL | 2015 |
|
RU2695785C2 |
| TRANSDERMAL THERAPEUTIC SYSTEM WITH ADHESION LAYER, METHOD OF SYSTEM SUBSTRATE SILICONISATION AND APPLICATION OF SUBSTRATE | 2005 |
|
RU2398567C2 |
| MATRIX BASED ON ACRYLIC ADHESIVE WITH COMPLEX OF TRANSDERMAL TRANSFER ACTIVATORS FOR TRANSDERMAL THERAPEUTIC SYSTEMS | 2023 |
|
RU2812184C1 |
| TRANSDERMAL THERAPEUTIC SYSTEM USING HEAT AVAILABLE TO ACCELERATE PENETRATION OF BIOLOGICALLY ACTIVE SUBSTANCES, AND APPLICATION THEREOF | 2004 |
|
RU2348397C2 |
| TRANSDERMAL THERAPEUTIC SYSTEM CONTAINING ASENAPINE | 2019 |
|
RU2798017C2 |
| PHARMACEUTICAL COMPOSITION FOR TRANSDERMAL THERAPEUTIC SYSTEM CONTAINING ALPRAZOLAM | 2018 |
|
RU2694232C1 |
| TRANSDERMAL THERAPEUTIC SYSTEM | 2006 |
|
RU2450805C2 |
